A randomised controlled trial comparing three methods of teaching home spirometry in adult patients with respiratory symptoms

ISRCTN ISRCTN18299685
DOI https://doi.org/10.1186/ISRCTN18299685
ClinicalTrials.gov (NCT) Nil known
Clinical Trials Information System (CTIS) Nil known
Integrated Research Application System (IRAS) 287426
Protocol serial number IRAS 287426
Sponsor North Bristol NHS Trust
Funder Southmead Hospital Charity
Submission date
13/04/2023
Registration date
18/05/2023
Last edited
15/07/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Spirometry is an important test in the assessment and monitoring of patients with respiratory symptoms. It measures how much air you can get in and out of your lungs and the total volume of air that you can get in and out. Due to the COVID-19 pandemic access to spirometry has become more limited meaning that patients are having to wait longer to have this test.
The aim of this study is to investigate whether patients can perform spirometry measurements at home and which method of teaching patients to perform the test works best.

Who can participate?
Patients aged 18 years or over who require spirometry as part of their standard of care

What does the study involve?
Participants will be allocated to one of three different groups:
Group 1 - Face to Face Teaching
The participant will attend the hospital for their spirometry appointment. At this appointment, they will also be taught how to use the home spirometry equipment and app. The participant will then take the equipment home and perform spirometry measurements.
Group 2 - Virtual Teaching
Participants will be sent the home spirometry equipment and the Spirobank Smart Spirometer Home Spirometry Patient Information Leaflet in the post. They will then have a virtual appointment with a member of the Respiratory Physiology team. At this appointment participants will be taught how to use the home spirometry equipment and app. The participant will then take the equipment home and perform spirometry measurements.
Participants will then attend the hospital for their spirometry appointment.
Group 3 - Self-Directed Learning
Participants will be sent the home spirometry equipment and the Spirobank Smart Spirometer Home Spirometry Patient Information Leaflet in the post. They will also be sent a link to a video demonstrating how to use the equipment. The participant will then take the equipment home and perform spirometry measurements. Participants will then attend the hospital for their spirometry appointment.
After performing home spirometry measurements, participants will email their results to the hospital. Participants will also be asked to complete a questionnaire, which asks questions about how they found using the home spirometry equipment.

What are the possible benefits and risks of participating?
There are no direct benefits to participants in the short term. However in the longer term if successful participants may be able to continue performing spirometry at home which may reduce the number of times that they need to attend appointments at the hospital. They may also gain more information about their respiratory health which might be useful.
Before taking part all participants will be screened to make sure the breathing tests will not pose a risk to them. In some circumstances such as if participants have recently undergone surgery the spirometry test should not be performed and therefore participants would not be able to participate in this study. The breathing tests may cause participants to feel slightly lightheaded or breathless, this is normal and should resolve after a few minutes.

Where is the study run from?
Southmead Hospital (UK)

When is the study starting and how long is it expected to run for?
September 2020 to June 2023

Who is funding the study?
Southmead Hospital Charity (UK)

Who is the main contact?
Dr Caitlin Morgan, caitlin.morgan@nbt.nhs.uk

Contact information

Dr Caitlin Morgan
Public

Learning and Research Building
Southmead Hospital
Bristol
BS10 5NB
United Kingdom

ORCiD logoORCID ID 0000-0001-7133-0195
Phone +44 (0)1174147925
Email caitlin.morgan@nbt.nhs.uk

Study information

Primary study designInterventional
Study designRandomized controlled trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleREmote teACHing of home SPIROmetry in patients with respiratory symptoms
Study acronymREACH SPIRO
Study objectivesRemote teaching of home spirometry (using the Spirobank Smart spirometer) produces consistent and acceptable lung function measurements when compared to face-to-face teaching on the same device and when compared to the gold standard (lab-based hospital spirometry).
Ethics approval(s)Approved 07/05/2021, Office for Research Ethics Committees Northern Ireland (ORECNI), Customer Care & Performance Directorate, Lissue Industrial Estate West, 5 Rathdown Walk, Moira Road, Lisburn, BT28 2RF, UK; +44 (0)28 95361407; RECA@hscni.net), ref: 21/NI/0063
Health condition(s) or problem(s) studiedRespiratory disease
InterventionSingle-centre unblinded randomized controlled trial of remote versus face-to-face teaching of home spirometry on the Spirobank smartmeter in patients presenting with respiratory symptoms. Participants will be randomized in a 1:1:1 ratio. The group allocated indicates which method of teaching that participant receives. Following consent patients were randomised using a secure web-based system (REDCap). It is not practical to conceal which arm a patient was randomised to from the perspective of the participant or the researcher.

Group 1 - Face to Face Teaching
The participant will attend the hospital for their spirometry appointment. At this appointment, they will also be taught how to use the home spirometry equipment and app. The participant will then take the equipment home and perform spirometry measurements.

Group 2 - Virtual Teaching
Participants will be sent the home spirometry equipment and the Spirobank Smart Spirometer Home Spirometry Patient Information Leaflet in the post. They will then have a virtual appointment with a member of the Respiratory Physiology team. At this appointment participants will be taught how to use the home spirometry equipment and app. The participant will then take the equipment home and perform spirometry measurements.
Participants will then attend the hospital for their spirometry appointment.

Group 3 - Self-Directed Learning
Participants will be sent the home spirometry equipment and the Spirobank Smart Spirometer Home Spirometry Patient Information Leaflet in the post. They will also be sent a link to a video demonstrating how to use the equipment. The participant will then take the equipment home and perform spirometry measurements. Participants will then attend the hospital for their spirometry appointment.

After performing home spirometry measurements, participants will email their results to the hospital. Participants will also be asked to complete a questionnaire, which asks questions about how they found using the home spirometry equipment.
Intervention typeMixed
Primary outcome measure(s)

Accuracy and acceptability of measurements produced by remote teaching of home spirometry (MIR Spirobank smartmeter) compared to face-to-face teaching and in-hospital spirometry (the gold standard). One or more home spirometry measurements of Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), FEV1/FVC and Peak Expiratory Flow Rate (PEFR) and forced expiratory flow (FEF) will be compared between each randomised group and hospital spirometry. Home spirometry recordings are submitted within 6 weeks of hospital spirometry.

Key secondary outcome measure(s)

1. Feasibility of bronchodilator reversibility performed at home, assessed using home spirometry measurements of FEV1, FVC, PEFR and FEF with subsequent measurements after a short-acting bronchodilator and hospital spirometry. Home spirometry recordings are submitted within 6 weeks of hospital spirometry.
2. Patient acceptability of performing home spirometry, assessed by qualitative analysis of feedback questionnaires following the completion of home and hospital spirometry
3. Factors that affect patient willingness, adherence and quality of home spirometry, assessed by qualitative analysis of feedback questionnaires following completion of home and hospital spirometry
4. Disease-specific effects in ILD and airway disease patients assessed using home and hospital spirometry measurements of FEV1, FVC, PEFR and FEF spirometry. Home spirometry recordings are submitted within 6 weeks of hospital spirometry

Completion date01/06/2023

Eligibility

Participant type(s)Patient
Age groupAdult
SexAll
Target sample size at registration100
Total final enrolment106
Key inclusion criteria1. Require spirometry as part of their routine clinical care
2. The participant has the required technology (smartphone or tablet and an internet connection) to enable the use of the home spirometry device
3. Able to give informed consent
Key exclusion criteria1. Age <18 years
2. Spirometry contraindicated
Date of first enrolment13/07/2021
Date of final enrolment24/05/2022

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

North Bristol NHS Trust
Southmead Hospital
Southmead Road
Westbury-on-trym
Bristol
BS10 5NB
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
IPD sharing planThe data-sharing plans for the current study are unknown and will be made available at a later date

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
HRA research summary 28/06/2023 No No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

15/07/2025: The intention to publish date was changed from 01/07/2024 to 01/08/2025.
17/04/2023: Trial's existence confirmed by the Office for Research Ethics Committees Northern Ireland (ORECNI).